Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 27c, beats revenue

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.18, $0.27 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Eton Pharmaceuticals (ETON) PT Raised to $65 at H.C. Wainwright
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%
• Bit Digital (BTBT) Misses Q2 EPS by 27c